补益强心片对心力衰竭患者血清线粒体偶联因子6、内源性前列环素的影响分析  

Effect of Buyi Qiangxin Tablets on Serum Mitochondrial Coupling Factor 6 and Endogenous Prostagycline in Patients with Heart Failure

作　　者：孙燕 李晓红 王丽 SUN Yan;LI Xiao-Hong;WANG Li(Hengshui People’s Hospital,Hengshui 053000 Hebei,China)

机构地区：[1]河北省衡水市人民医院,河北衡水053000

出　　处：《广州中医药大学学报》2023年第11期2731-2738,共8页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(编号:81804045)。

摘　　要：【目的】观察补益强心片对慢性心力衰竭(CHF)患者血清线粒体偶联因子6(CF6)、内源性前列环素(PGI2)的影响。【方法】采用回顾性研究方法,收集2019年10月至2021年10月在河北省衡水市人民医院就诊的102例CHF气虚血瘀兼水停证患者,根据治疗方法的不同将患者分为观察组和对照组,每组各51例。对照组给予西医常规治疗,观察组在对照组的基础上给予补益强心片治疗,疗程为4周并随访1年。观察2组患者治疗前后左室射血分数(LVEF)、6 min步行距离(6MWD)、血清CF6、PGI2及血清氨基末端B型钠尿肽前体(NT-proBNP)、心肌肌钙蛋白I(cTnI)水平的变化情况,并比较2组患者的临床疗效、不良反应发生率及1年内再入院率。【结果】(1)治疗4周后,观察组的总有效率为94.12%(48/51),对照组为70.59%(36/51),组间比较(χ^(2)检验),观察组的临床疗效明显优于对照组(P<0.01)。(2)治疗后,2组患者的LVEF、6MWD均较治疗前明显改善(P<0.05),且观察组对LVEF、6MWD的改善幅度均明显优于对照组(P<0.01)。(3)治疗后,2组患者血清CF6、NT-proBNP、cTnI水平均较治疗前降低(P<0.05),血清PGI2水平均较治疗前升高(P<0.05),且观察组对血清CF6、NTproBNP、cTnI水平的降低幅度及对血清PGI2水平的升高幅度均明显优于对照组(P<0.01)。(4)观察组的不良反应发生率为3.92%(2/51),对照组为7.84%(4/51),组间比较,差异无统计学意义(P>0.05)。(5)随访1年,观察组的1年内再入院率为1.96%(1/51),明显低于对照组的17.65%(9/51),组间比较,差异有统计学意义(P<0.05)。【结论】补益强心片治疗CHF气虚血瘀兼水停证患者疗效确切,可有效改善患者心功能,提高患者运动耐力,减轻心肌细胞受损程度,调节血清CF6、PGI2表达,降低再入院率,且不良反应相对较少,具有较高的安全性。Objective To observe the effects of Buyi Qiangxin Tablets on serum mitochondrial coupling factor 6(CF6)and endogenous prostacyclin(PGI2)in patients with chronic heart failure(CHF).Methods A retrospective study was conducted in 102 patients with CHF of qi deficiency and blood stasis complicated with fluid retention syndrome who sought medical consultation in Hengshui People’s Hospital in Hebei Province from October 2019 to October 2021,and the patients were divided into an observation group and a control group according to the treatment methods,with 51 cases in each group.The control group was treated with conventional western medicine,and the observation group was treated with Buyi Qiangxin Tablets orally on the basis of treatment for the control group.Both groups were treated for 4 weeks and were followed up for one year.The changes of left ventricular ejection fraction(LVEF),6-minute walking distance(6MWD),and serum levels of CF6,PGI2,N-terminal pro-brain natriuretic peptide(NT-proBNP),and cardiac troponin I(cTnI)in the two groups were observed before and after treatment.Moreover,the clinical efficacy,the incidence of adverse reactions and the readmission rate within one year in the two groups were compared.Results(1)After 4 weeks of treatment,the total effective rate of the observation group was 94.12%(48/51),and that of the control group was 70.59%(36/51),and the intergroup comparison(tested by chi-square test)showed that clinical efficacy of the observation group was significantly superior to that of the control group(P<0.01).(2)After treatment,the LVEF and 6MWD of patients in the two groups were significantly improved compared with those before treatment(P<0.05),and the improvement of LVEF and 6MWD in the observation group was significantly superior to that in the control group(P<0.01).(3)After treatment,the serum CF6,NT-proBNP,and cTnI levels in the two groups were lower than those before treatment(P<0.05),and the serum PGI2 level was increased compared with that before treatment(P<0.05).The degree of th

关 键 词：补益强心片 慢性心力衰竭 气虚血瘀兼水停证 线粒体偶联因子6(CF6) 内源性前列环素(PGI2) 

分 类 号：R259.416[医药卫生—中西医结合]